Fenwick & West represented KalVista Pharmaceuticals Ltd., a privately-held biopharmaceutical company, in its definitive share purchase agreement pursuant to which the shareholders of KalVista will become the majority owners of Carbylan Therapeutics, Inc. (NASDAQ: CBYL), a clinical-stage specialty pharmaceutical company.
The Fenwick transaction team included corporate lawyers Lynda Twomey, David Michaels, Effie Toshav, Kee Kim, Andrew Albertson, Anna Szygorski, Brady Douglas and Can Sun; executive compensation and employee benefits lawyers Blake Martell and Elizabeth Gartland; and securities lawyers Robert Freedman and Julia Forbess; and IP lawyers Stefano Quintini and Jake Handy.